Brief: Merus’ Zeno Interim Data Continues To Demonstrate Robust And Durable Responses In Nrg1+ Cancer
23/10/2023 13:54
Oct 23 (Reuters) - Merus NV MRUS.O :
* MERUS’ ZENO INTERIM DATA CONTINUES TO DEMONSTRATE ROBUST
AND
DURABLE RESPONSES IN NRG1+ CANCER
* MERUS NV - SUFFICIENT CLINICAL DATA EXPECTED IN 1H24 TO
SUPPORT
POTENTIAL BLA SUBMISSIONS
Source text for Eikon: ID:nGNX17nSFs
Further company coverage: MRUS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab